Research literature

Publications

Explore a growing selection of published research associated with products in our catalogue. Find papers by product, journal, year or keyword.

448 selected publications13 products

448 publications · Showing 1–10

Cell

2026

Sensing endoplasmic reticulum redox state by ethylene receptors

DOI: 10.1016/j.cell.2026.04.004

Read paper View YEASEN 11184

Nature Communications

2026

First published 27 January 2026

The functional landscape of alternative splicing in hematopoietic lineage commitment

The authors report using YEASEN 11184 for real-time qPCR.

DOI: 10.1038/s41467-026-68811-8

Read paper View YEASEN 11184

Cell Reports

2026

FASN inactivation-induced progranulin (GRN) expression promotes lysosome-dependent cell death to suppress leukemogenesis

DOI: 10.1016/j.celrep.2026.117042

Read paper View YEASEN 11184

Cell Reports

2026

Spatial and single-cell transcriptomics reveals senescence-associated changes in MIA-induced ASD male mouse brain

DOI: 10.1016/j.celrep.2026.117191

Read paper View YEASEN 11184

Cell Reports

2026

Targeting EP2/EP4-driven expansion of suppressive VSIG4high macrophages overcomes immunotherapy resistance in colorectal cancer

DOI: 10.1016/j.celrep.2026.117450

Read paper View YEASEN 40801

Cell Reports

2026

Trans-presentation of IL-6Rα by macrophages drives colorectal cancer development

DOI: 10.1016/j.celrep.2026.117549

Read paper View YEASEN 20350

Molecular Cell

2026

Intrinsic bias of the genetic code shapes the folding and stability landscapes of microproteins

DOI: 10.1016/j.molcel.2026.04.021

Read paper View YEASEN 20350

Molecular Cell

2026

IS110 transposon utilizes two mechanistically distinct RNA-guided transposition pathways

DOI: 10.1016/j.molcel.2026.05.009

Read paper View YEASEN 11184

Cell Reports Medicine

2026

5-HT reuptake blockade induces pyroptosis in BRAFV600E-mutated melanomas via remodeling histone serotonylation

DOI: 10.1016/j.xcrm.2025.102537

Read paper View YEASEN 10510

Cell Reports Medicine

2026

A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance

DOI: 10.1016/j.xcrm.2026.102932

Read paper View YEASEN 40807

For current product specifications and instructions, see our product documents.